ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Verzenio — Worldwide revenue growth YoY by Year
Verzenio — Worldwide revenue growth YoY (%) (%)
Eli Lilly Verzenio — Worldwide revenue growth YoY: 8.0% in FY2025, down 29.0 pts from a year earlier.
Latest, FY2025
8.0%
Period ended Dec 31, 2025
Change on a year earlier
-29.0 pts
37.0% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Verzenio | 3,464 | 2,259 | 5,723 | 5,307 | 8”
Source: Form 10-K FY2025 (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Verzenio — Worldwide revenue growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.0% | -29.0 pts | Form 10-K FY2025 (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 37.0% | -19.0 pts | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 56.0% | -28.0 pts | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 84.0% | +36.0 pts | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 48.0% | -9.0 pts | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 57.0% | – | Form 10-K FY2020 (filed 2021-02-17) ↗ |
Cite this data
StockData. (2026). Eli Lilly Verzenio — Worldwide revenue growth YoY (%), annual FY2020–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-verzenio-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.